Skip to main content
. 2021 Apr 21;10(5):967. doi: 10.3390/cells10050967

Figure 4.

Figure 4

Selection and pretreatment of expanded PBNK cells with Daratumumab to increase synergy in combinatorial therapy with mAbs. (a) Graph with the specific lysis results in a combinatorial therapy with PBNK cells (R = 0.46 and R = 0.24) and Daratumumab against MM cell lines RPMI 8226 and U266. Measured using the bioluminescence imaging assay at a 1:1 effector-to-target ratio for 24 h. (b) Summary graph with the viability over time of PBNK cells after treatment with Daratumumab (PBNK-CD38−) for 48 h, compared to the untreated population. (c) FACS phenotypic analysis comparing the PBNK cells treated and not treated with Daratumumab for 48 h. (d) Graph with the cytotoxicity of pretreated PBNK-CD38− cells and original population with heterogeneous expression of CD38 against RPMI 8226 with Daratumumab. Combinatorial cytotoxicity was measured using the bioluminescence imaging assay at 1:1 effector-to-target ratio for 24 h. Data in (b) are means ± SEM of three expanded PBNK cell donors. Data in (a,d) are presented as means ± SD of each expanded PBNK cells in three technical replicates. *, p < 0.05, **, p < 0.01, ***, p < 0.001, based on Student’s t-test.